Zentralbl Chir 2012; 137(1): 32-37
DOI: 10.1055/s-0031-1283887
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Kriterien der Resektabilität von malignen extrahepatischen Gallengangstumoren

Criteria for the Resectability of Malignant Extrahepatic Bile Duct Tumours
S. Kissenkoetter
1   Krankenhaus Dresden-Friedrichstadt, Klinik für Allgemein- und Viszeralchirurgie, Dresden, Deutschland
,
H. Witzigmann
1   Krankenhaus Dresden-Friedrichstadt, Klinik für Allgemein- und Viszeralchirurgie, Dresden, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
16 February 2012 (online)

Zusammenfassung

Hintergrund: Karzinome der extrahepatischen Gallenwege sind bei der Erstdiagnose häufig fortgeschritten. Die Resektion stellt die einzige potenziell kurative Behandlung dar. Es gibt große Unterschiede in den publizierten Resektionsraten.

Methodik: In diesem Artikel werden die Kriterien der Resektabilität maligner extrahepatischer Gallengangstumoren anhand einer umfassenden Literaturrecherche mittels PubMed erarbeitet, welche die Ergebnisse aus randomisierten, kontrollierten Studien (RCT), Übersichtsarbeiten, Metaanalysen und Kohortenstudien einschließt.

Ergebnisse: Eine detaillierte präoperative Diagnostik und die Erfahrung des Chirurgen sind entscheidend für die Definition der Resektabilität. Klatskintumoren: Regionäre N1-Lymphknotenmetastasen sind keine Kontraindikation für eine Resektion. Eine erweiterte Lymphadenektomie bei paraaortaler Metastasierung ist nur bei selektionierten Patienten indiziert. Der Stellenwert der Lebertransplantation nach neoadjuvanter RCT (sog. Mayo-Klinik-Protokoll) bei nicht resektablen Tumoren muss in weiteren Studien evaluiert werden. Die R1-Resektion bietet einen signifikanten Benefit gegenüber dem palliativen Stenting. Distale Cholangiokarzinome: Der Befall der regionären Lymphknoten ist keine Kontraindikation zur Resektion. Der Verdacht auf eine Infiltration der mesenterico-portalen Venen ist keine Kontraindikation zur Resektion. Die Segmentresektion von V. portae / V. mes. sup. ist sicher und erhöht die Morbidität und Mortalität nicht. Eine Resektion bei Tumorinfiltration des Truncus coeliacus oder der A. mes. sup. ist onkologisch nicht sinnvoll. Zum Wert einer palliativen R1 / R2-Resektion gibt es keine Evidenz.

Schlussfolgerung: Aus anatomischen Gründen liegen die Resektionsraten beim distalen Cholangiokarzinom höher als beim Klatskintumor. Die Beurteilung, ob eine kurative Resektion möglich ist, erfordert insbesondere beim Klatskintumor eine detaillierte präoperative Diagnostik und Konditionierung des Patienten.

Abstract

Background: Most cholangiocarcinomas of the extrahepatic bile duct are diagnosed at an advanced stage. Surgery represents the only potentially curative treatment. An assessment as to whether a curative resection is possible is based on the experience of the treating physicians.

Methods: The present guidelines are based on comprehensive literature surveys in PubMed, including results from randomised controlled trials, systematic reviews and meta-analyses, and cohort studies.

Results: The experience of the surgeon is determining for defining criteria for resection. The surgical standards for treating Klatskin tumours are extended liver resections. Liver transplantation after neoadjuvante chemo / radiation therapy offers good results. N1 regional lymph node metastases are not a contraindication for resection. R1 resection is justified as a very efficient palliative procedure. The surgical standard for treating distal cholangiocarcinoma is the partial pancreatoduodenectomy. Infiltration of the mesenterico-portal veins or regional lymph nodes is not a contraindication for resection. However, resection has not been shown to provide survival benefit if the coeliac trunk or the superior mesenteric artery is infiltrated. There is no evidence for or against a palliative R1/R2 resection.

Conclusions: For anatomic reasons, the resection rates for distal cholangiocarcinoma are higher than those for Klatkin tumours. The decision as to whether or not a curative resection is possible, especially for Klatskin tumour, requires detailed preoperatzive diagnostics and a conditioning of the patient.

 
  • Literatur

  • 1 Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours (Uicc International Union Against Cancer). 7th. ed. New York: John Wiley & Sons; 2010
  • 2 Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 1965; 38: 241-256
  • 3 Kloek JJ, Ten KateFJ, Busch OR et al. Surgery for extrahepatic cholangiocarcinoma: predictors of survival. HPB (Oxford) 2008; 10: 190-195
  • 4 Jarnagin WR, Fong Y, DeMatteo RP et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517
  • 5 Kawasaki S, Imamura H, Kobayashi A et al. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg 2003; 238: 84-92
  • 6 Klempnauer J, Ridder GJ, von Wasielewski R et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997; 15: 947-954
  • 7 Neuhaus P, Jonas S, Bechstein WO et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999; 230: 808-818
  • 8 Pichlmayr R, Weimann A, Klempnauer J et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996; 224: 628-638
  • 9 Seyama Y, Kubota K, Sano K et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 2003; 238: 73-83
  • 10 Kondo S, Hirano S, Ambo Y et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg 2004; 240: 95-101
  • 11 Klempnauer J, Ridder GJ, Werner M et al. What constitutes long-term survival after surgery for hilar cholangiocarcinoma?. Cancer 1997; 79: 26-34
  • 12 Hemming AW, Reed AI, Fujita S et al. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005; 241: 693-699
  • 13 Otto G, Hoppe-Lotichius M, Bittinger F et al. Klatskin tumour: meticulous preoperative work-up and resection rate. Z Gastroenterol 2011; 49: 436-442
  • 14 Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975; 140: 170-178
  • 15 Vogl TJ, Schwarz WO, Heller M et al. Staging of Klatskin tumours (hilar cholangiocarcinomas): comparison of MR cholangiography, MR imaging, and endoscopic retrograde cholangiography. Eur Radiol 2006; 16: 2317-2325
  • 16 Chen HW, Lai EC, Pan AZ et al. Preoperative assessment and staging of hilar cholangiocarcinoma with 16-multidetector computed tomography cholangiography and angiography. Hepatogastroenterology 2009; 56: 578-583
  • 17 Cho ES, Park MS, Yu JS et al. Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography. J Comput Assist Tomogr 2007; 31: 72-78
  • 18 Unno M, Okumoto T, Katayose Y et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg 2007; 14: 434-440
  • 19 Anderson CD, Rice MH, Pinson CW et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8: 90-97
  • 20 Corvera CU, Blumgart LH, Akhurst T et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008; 206: 57-65
  • 21 Reinhardt MJ, Strunk H, Gerhardt T et al. Detection of Klatskin’s tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET / CT: preliminary results for 22 patient studies. J Nucl Med 2005; 46: 1158-1163
  • 22 Petrowsky H, Wildbrett P, Husarik DB et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45: 43-50
  • 23 Kipp BR, Stadheim LM, Halling SA et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004; 99: 1675-1681
  • 24 Weber SM, DeMatteo RP, Fong Y et al. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg 2002; 235: 392-399
  • 25 Connor S, Barron E, Wigmore SJ et al. The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg 2005; 9: 476-480
  • 26 Khan SA, Davidson BR, Goldin R et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl. 06) VI1-VI9
  • 27 Burke EC, Jarnagin WR, Hochwald SN et al. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998; 228: 385-394
  • 28 DeOliveira ML, Schulick RD, Nimura Y et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011; 53: 1363-1371
  • 29 European Hepato-Pancreato-Biliary Association (E-AHPBA). Perihilar Cholangiocarcinoma International Registry (CholangioCa Registry) (18.10.2011). Im Internet: www.cholangioca.org Stand: 18.10.2011
  • 30 Witzigmann H, Wiedmann M, Wittekind C et al. Therapeutical concepts and results for klatskin tumors. Dtsch Arztebl Int 2008; 105: 156-161
  • 31 Capussotti L, Vigano L, Ferrero A et al. Local surgical resection of hilar cholangiocarcinoma: Is there still a place?. HPB (Oxford) 2008; 10: 174-178
  • 32 Tsao JI, Nimura Y, Kamiya J et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 2000; 232: 166-174
  • 33 Neuhaus P, Jonas S, Settmacher U et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 2003; 388: 194-200
  • 34 Sano T, Shimada K, Sakamoto Y et al. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg 2006; 244: 240-247
  • 35 Liu CL, Fan ST, Lo CM et al. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg 2006; 93: 1488-1494
  • 36 Baton O, Azoulay D, Adam DV et al. Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes. J Am Coll Surg 2007; 204: 250-260
  • 37 Nagino M, Nimura Y, Nishio H et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg 2010; 252: 115-123
  • 38 Lee SG, Song GW, Hwang S et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asian experience. J Hepatobiliary Pancreat Sci 2010; 17: 476-489
  • 39 Ito F, Agni R, Rettammel RJ et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 2008; 248: 273-279
  • 40 Kitagawa Y, Nagino M, Kamiya J et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001; 233: 385-392
  • 41 Kosuge T, Yamamoto J, Shimada K et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230: 663-671
  • 42 Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: the Nagoya experience. HPB (Oxford) 2005; 7: 259-262
  • 43 Witzigmann H, Berr F, Ringel U et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1 / r2 resection. Ann Surg 2006; 244: 230-239
  • 44 Zhang BH, Cheng QB, Luo XJ et al. Surgical therapy for hiliar cholangiocarcinoma: analysis of 198 cases. Hepatobiliary Pancreat Dis Int 2006; 5: 278-282
  • 45 Bundesärztekammer. Richtlinie zur Organtransplantation gemäß § 16 TPG. Dtsch Arztebl 2008; 105: 46-67
  • 46 Iwatsuki S, Todo S, Marsh JW et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187: 358-364
  • 47 Robles R, Figueras J, Turrion VS et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004; 239: 265-271
  • 48 Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-458
  • 49 Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int 2010; 23: 692-697
  • 50 Alden ME, Waterman FM, Topham AK et al. Cholangiocarcinoma: clinical significance of tumor location along the extrahepatic bile duct. Radiology 1995; 197: 511-516
  • 51 DeOliveira ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-762
  • 52 Argani P, Shaukat A, Kaushal M et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001; 91: 1332-1341
  • 53 Sakamoto Y, Kosuge T, Shimada K et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 2005; 137: 396-402
  • 54 Allen PJ, Reiner AS, Gonen M et al. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. HPB (Oxford) 2008; 10: 341-346
  • 55 Nagakawa T, Kayahara M, Ikeda S et al. Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 2002; 9: 569-575
  • 56 Todoroki T, Kawamoto T, Koike N et al. Treatment strategy for patients with middle and lower third bile duct cancer. Br J Surg 2001; 88: 364-370
  • 57 Kondo S, Takada T, Miyazaki M et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg 2008; 15: 41-54
  • 58 Adler G, Seufferlein T, Bischoff SC et al. S3-Leitlinie „Exokrines Pankreaskarzinom" 2006. Im Internet: www.awmf.org/uploads/tx_szleitlinien/032-010_S3_Exokrines_Pankreaskarzinom_Leitlinie_10-2006_10-2011.pdf Stand: 18.10.2011
  • 59 Murakami Y, Uemura K, Hayashidani Y et al. Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J Surg 2007; 31: 337-342
  • 60 Kayahara M, Nagakawa T, Ohta T et al. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 1999; 229: 76-83
  • 61 Jang JY, Kim SW, Park DJ et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 2005; 241: 77-84